---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-018381"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2021-09-10T23:59:59+00:00"
generated_at: "2026-06-29T04:30:51.088244+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals promotes Mary DiBiase to COO effective Sep 8, 2021

## Summary
- Dr. DiBiase previously SVP of Technical Operations & Quality; now oversees program/alliance mgmt and IT.
- Annual base salary $409,500; eligible for annual cash incentive at 40% of base salary target.
- Granted 27,000 RSUs vesting equally over three years.
- Severance terms include 12-month base salary continuation and accelerated equity vesting on qualifying termination.
- Promotion supports late-stage development of mavorixafor and preparations for potential commercialization.

## SEC filing metadata
- accession: 0001628280-21-018381
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2021-09-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/0001628280-21-018381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/xfor-20210910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-018381
- JSON: https://secwatch.observer/filing/0001628280-21-018381.json
- Plain text: https://secwatch.observer/filing/0001628280-21-018381.txt

## Key facts
- Executive change
  Mary DiBiase was appointed as Chief Operating Officer at X4 Pharmaceuticals, Inc.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On September 8, 2021, X4 Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mary DiBiase, Ph.D., age 60, as the Company’s Chief Operating Officer, effective as of September 8, 2021 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/0001628280-21-018381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.